2 terminated, 1 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow MK-8353: new trials by email Literature Review of MK-8353 trials Research Report on MK-8353
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) MK-8353, Selumetinib - Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 30 | 2019-02-22 | 2023-07-27 |
| Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) MK-8353, Pembrolizumab - Neoplasms, Colorectal Cancer | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 111 | 2017-01-13 | 2024-11-21 |
| A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) MK-8353 - Tumor, Solid | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 25 | 2011-11-04 | 2020-04-02 |
Neoplasms (2) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1)
Canada (2) · United States (2) · Switzerland (1)
PMID 29467321, PMID 37040046, PMID 39276176
2016 (1)